Skip to main content
Caplight Logo









Genevant Sciences

Genevant Sciences

Private
Vancouver, British ColumbiaHealthcare & Life Scienceshttps://www.genevant.com/

Last Round

Corporate Funding

Jul 31, 2020

Est. Valuation

$87.5M

Total Funding Raised

$40M

Company Overview

Genevant Sciences is a biotechnology company that provides nucleic acid delivery technology, including lipid nanoparticle (LNP) platforms, for the development of RNA-based therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

lipid nanoparticle deliveryLNP technologynucleic acid deliveryRNA deliverytechnology licensingdrug delivery platformmRNA deliverypicks and shovels biotechsiRNA deliverygene editing deliveryintellectual property licensingRNA therapeuticsligand conjugate deliverypharma partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Genevant Sciences Comparables

Compare Genevant Sciences with similar companies based on industry and business-model similarity.

Genevant Sciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Acuitas Therapeutics
92%
NanoVation Therapeutics
88%
Ethris
77%

Genevant Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingJul 31, 2020
SeedApr 11, 2018

Key People

Founding team and executive leadership

James Heyes

Chief Executive Officer

Executive Team

Ed Yaworski

Chief Technology Officer, Vice President, Pharmaceutical Development

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 27, 2024

    Monthly visitors increased 555% MoM, reaching 7.2K.

  • Aug 13, 2023

    Grew 18% QoQ from 40 to 47 employees.

Genevant Sciences Filings

Explore SEC and related filing metadata, where available.

Genevant Sciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Genevant Sciences's valuation, stock price, and market status.

Is Genevant Sciences a public or private company?

Genevant Sciences is a private company.

What is the current stock price of Genevant Sciences?

Genevant Sciences is a private company with no public stock price. No recent secondary market data is available.

How much is Genevant Sciences worth (valuation)?

Genevant Sciences's valuation is estimated at $87.5M based on funding round data.

Can I buy Genevant Sciences stock?

Genevant Sciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Genevant Sciences's last funding round?

Genevant Sciences's most recent funding round was Corporate Funding on April 11, 2018.

Who are the main investors in Genevant Sciences?

Investor information for Genevant Sciences is not publicly disclosed.

Will Genevant Sciences IPO soon?

No public IPO plans have been announced for Genevant Sciences.

How can I track Genevant Sciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Genevant Sciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersVancouver, British Columbia
Employee Range42
Year Founded2018
Last FundingJul 31, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?